Sevabertinib, targeting HER2 and EGFR mutations, received FDA breakthrough designation for HER2+ NSCLC, showing a 59% overall ...

They plan to run similar trials on seven more patients over the next three years, backed by $4 million from the National ...

Pancreatic ductal adenocarcinoma (PDAC) is the most lethal form of pancreas cancer. It's also the most common form of the ...

A trial has shown boosting diet with supplements could halt tumour growth in prostate cancer patients - opening the door to a whole new approach to cancer treatment ...

Irene Blair was expected to have another six to eight months to live in June, after her pancreatic cancer rapidly advanced to ...

Randomness inside cells can decide whether a cancer returns after chemotherapy or whether an infection survives antibiotics.

Datopotamab deruxtecan received FDA approval for HR+/HER2– breast cancer, improving progression-free survival and overall ...

Cancer imaging is entering a phase where malignant cells no longer hide in murky grayscale but flare into view with surgical precision. Across operating rooms, scanners, and even blood tests, ...

Researchers at Case Western Reserve University have developed a treatment for advanced prostate cancer that could eliminate a side effect so debilitating that patients often refuse the life-saving ...

Breakthrough Therapy Designation granted to zoldonrasib for the treatment of adult patients with KRAS G12D-mutated locally ...

Zoldonrasib targets KRAS G12D-mutated non-small cell lung cancer, receiving FDA breakthrough therapy designation for its ...

More than 67,000 Americans are expected to be diagnosed with pancreatic cancer this year, but a new blood test is offering ...